OVERVIEW

Cancer Summaries and Commentaries™: Report From Chicago on Advances in Genitourinary Cancers is organized by Physicians' Education Resource, LLC (PER).

Release Date: July 31, 2019
Expiration Date: July 31, 2020

Target Audience:
This educational activity is directed toward medical oncologists and fellows who treat patients with GU cancers. Surgical oncologists, radiation oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of GU cancers are also invited to participate.

Accreditation/Credit Designation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
This online activity is designed to update physicians on data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, held in June in Chicago, IL. Cancer Summaries and Commentaries™: Report From Chicago on Advances in Genitourinary Cancers online continuing medical education (CME) activity facilitates critical assessment and clinical integration of new evidence, when appropriate. The activity reviews 5 abstracts with some of the most compelling and clinically relevant genitourinary (GU) cancer presentations from the meeting. For each abstract, a short summary of key clinical data is accompanied by expert perspectives that provide insight into how clinicians can apply these findings to their clinical practice to improve patient care.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Understand designs and endpoints from recently completed and ongoing clinical trials evaluating novel strategies for the management of patients with GU malignancies
• Interpret key findings from recent practice-changing clinical trials that evaluated novel strategies for the treatment of GU malignancies.
• Integrate emerging evidence into clinical context concerning novel agents and approaches for the management of GU malignancies.